When it binds, the pituitary releases a pulse of growth hormone. Ipamorelin is a synthetic pentapeptide — a chain of just five amino acids — that mimics ghrelin and binds to the growth hormone secretagogue receptor 1a (GHS-R1a) in the pituitary gland. Available data support increases in GH and IGF-1 levels with GHS treatment, but provide few objective insights on the effects of these drugs on body composition or other important endpoints. Nass and colleagues, in a two-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial of 65 healthy elderly patients, found that daily ibutamoren increased GH and IGF-I levels to those of healthy young adults without serious adverse effects.
Fewer than 30% of researchers achieve meaningful growth hormone amplification with ipamorelin monotherapy. While the above studies observed numerous AEs, another randomized, double-blind, placebo-controlled trial evaluating the effects of 4 weeks of ibutamoren administration in 32 healthy elderly patients observed no AEs(63). This difference impacts the GH release pattern (pulsatile vs flat), long-term pituitary function, cost, side effect profile, and how the body utilizes the growth hormone. At 12 months, a 0.14 mmol/L decrease in LDL cholesterol was observed with ibutamoren treatment, although no changes in total testosterone levels were observed.
Activation of these two receptors affects several downstream signaling pathways, culminating in a host of antifibrotic, anabolic, vasodilative, cardioprotective, and anti-inflammatory effects (34). The study’s results also emphasize the role of sermorelin as a potent GH and IGF-1 stimulator, which can yield significant increases in lean body mass. Despite these shortcomings, these findings highlight that sermorelin can lead to elevations in IGF-1 when used in conjunction with other GHS, showing the potential role of sermorelin in the treatment of hypogonadism. Additionally, the lack of comparator groups receiving GHS monotherapy and data regarding changes in body composition restrict the ability to fully understand the impact of the individual GHS.
Following this, GH, IGF-1, skeletal muscle function, body composition, and endocrine-metabolic functions were measured as outcomes. Consistent with this, patients’ waist-hip ratio and GH peak following sermorelin actually showed an age-independent inverse correlation. All 10 elderly men were given 14 days of twice daily injections of either low (0.5 mg) or high dose (1 mg) sermorelin which was then held for 14 days before being restarted for another 14-day period. It was noted that both peptides increased GH by a similar magnitude; however, sermorelin also produced small acute rises in prolactin, FSH, and LH. Sermorelin has been employed in both the diagnosis and treatment of GH deficiency although there is limited research on its use in the setting of hypogonadism (23). GHRH receptor activation leads to cAMP production via the Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways (24). The GHS consist of a variety of synthetic peptide or non-peptide agents that stimulate endogenous GH release.
Interestingly, a decrease in mean systolic blood pressure was observed as an effect of sermorelin treatment. However, as with the Corpas et al. study, no significant changes in testosterone levels were observed. This suggests that the timing and frequency of sermorelin treatment significantly affects IGF-1 levels, with a higher frequency of administration resulting in more significant IGF-1 increases. Essentially, sermorelin was found to augment the duration of rhythmic GH release without pushing serum levels above physiologic norms. Sermorelin therapy almost doubled the 12-h mean amount of GH released, but no significant changes to mean peak amplitude and number of peaks were observed. The older men had lower baseline IGF-1 levels when compared to the younger men but sermorelin treatment resulted in elevations in IGF-1 in a dose-response fashion to levels approaching those of the younger men. Measured outcomes included serum GH, IGF-1, IGFBP-3, and testosterone levels in addition to body weight, BMI, and waist-hip ratio.
Growth hormone is not a direct muscle builder in the way testosterone is. Training intensity, protein intake, sleep quality, and insulin signaling all modulate IGF-1 levels. Growth hormone does not directly stimulate muscle protein synthesis the way testosterone does. If you're curious about the head-to-head between ipamorelin and sermorelin specifically, we have a detailed breakdown in our Ipamorelin vs Sermorelin comparison. For body recomposition, a second injection in the morning (fasted) or post-workout adds additional GH stimulus without compounding side effects. GH itself has sleep-promoting properties — GH receptors are present in sleep-regulatory brain regions, and GH administration in clinical settings consistently improves sleep architecture. The improved sleep quality many users report isn't a side effect or placebo.

Gender: Female

Social links